<DOC>
	<DOCNO>NCT01902576</DOCNO>
	<brief_summary>The purpose study develop validate endpoint measure accurately determine whether patient respond treatment chronic Graft-versus-Host Disease ( GVHD ) . Hopefully , also lead well able predict patient respond therapy .</brief_summary>
	<brief_title>Chronic GVHD Response Measures Validation</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Age 7 year old Prior first allogeneic stem cell transplant , graft source , donor type , GVHD prophylaxis . Diagnosis chronic GVHD accord criterion diagnosis score group NIH consensus conference ( Patient must least one diagnostic manifestation chronic GVHD one distinctive manifestation pathological confirmation diagnosis . Concurrent acute GVHD manifestation allow long least one classic chronic manifestation present . ) Initiation new systemic treatment chronic GVHD past 4 week anticipate within next 4 week . Systemic treatment define medication intervention intend systemic effect , include extracorporeal photopheresis , regardless prior line therapy prior treatment agent ( ) . If patient restart treatment previously expose , must least 4 week restart . No evidence persistent progressive malignancy time enrollment Evaluation transplant center time study enrollment , agreement reevaluate transplant center four subsequent time : 3 month , 6 month , 18 month enrollment another treatment add chronic GVHD . Signed , inform consent Inability comply study procedure Complete resolution chronic GVHD time enrollment ( patient must measurable chronic GVHD activity )</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>